Mesenchymal stem cells ameliorate cisplatin‑induced acute kidney injury via let‑7b‑5p
Quick Facts
- Publication title: Mesenchymal stem cells ameliorate cisplatin‑induced acute kidney injury via let‑7b‑5p
- Journal: Cell Tissue Res
- Year: 2022
- DOI: 10.1007/s00441-022-03729-3
- PMID/PMCID: 36543894; 3064140
Research overview
Acute kidney injury (AKI) is a clinically common kidney disease. Let-7b-5p downregulation may lead to increased renal AKI susceptibility, thus indicating that this miRNA is a potential driver of the MSC treatment response in AKI.
Key findings
Acute kidney injury (AKI) is a clinically common kidney disease.
Age is an important factor that contributes to the susceptibility to AKI.
Mesenchymal stem cells (MSCs) are a promising therapy for AKI, and miRNAs in exosomes (Exos) derived from MSCs are an important aspect of MSC treatment.
However, the therapeutic effect of miRNA from MSC-derived Exos on AKI and the related mechanism have not been fully clarified.
Echo Biotech Role
Echo Biotech contributed EV isolation and purification, EV characterization; the study also used or cited Exosupur®.
Related platforms: Exoomics®, Research Reagents & Tools
Related services and capabilities: Cell-Culture Supernatant EV Isolation & Purification, EV Basic Characterization (TEM/NTA/WB), Research Reagent / Product Supply
Related products or reagents: Exosupur® EV Isolation/Purification Kit
References
Original publication: Mesenchymal stem cells ameliorate cisplatin‑induced acute kidney injury via let‑7b‑5p Cell Tissue Res. 2022. DOI: 10.1007/s00441-022-03729-3. PMID/PMCID: 36543894; 3064140.